GlassScriptPhysician profile
Gregory N Henson
NPI 1437135191
$3,993.63
in general payments reported to CMS, 2019-2025
31 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $777 · 2020: $742 · 2021: $445 · 2022: $679 · 2023: $680 · 2024: $400 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $623.67 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $500.29 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $489.84 | 2019-2024 | Evenity, Prolia, Otezla |
| Abbvie INC. | $358.90 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $329.76 | 2019-2022 | |
| Novo Nordisk INC | $295.37 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $289.79 | 2020-2025 | |
| Astellas Pharma US INC | $160.65 | 2019-2023 | Veozah |
| Lilly USA, LLC | $127.66 | 2020-2025 | Mounjaro, Zepbound, Amyvid |
| Merck Sharp & Dohme LLC | $115.84 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $77.05 | 2019-2020 | |
| Amarin Pharma, INC. | $75.51 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $70.96 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $61.36 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $51.06 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $40.06 | 2019-2023 | |
| Radius Health, INC. | $36.68 | 2019 | |
| Phathom Pharmaceuticals, INC. | $34.31 | 2024-2025 | Voquezna |
| Abiomed | $32.22 | 2024 | Impella |
| Tela Bio, INC. | $31.94 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.58 | 2019-2021 | |
| Shield Therapeutics INC | $20.65 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.61 | 2024 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $17.30 | 2021 | |
| Sanofi Pasteur INC. | $17.20 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.84 | 2025 | Caplyta |
| Eisai INC. | $15.93 | 2020 | |
| Exact Sciences Corporation | $14.55 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $14.34 | 2023 | Quviviq |
| Allergan, INC. | $12.16 | 2020 | |
| Perspectum Diagnostics LTD | $11.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Henson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.